CI · NYQ · Healthcare
The Cigna Group
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 1131.79
Market price
USD 275.28
Implied upside
+311.1%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 315.3bn | USD 363.1bn | USD 418.1bn | USD 481.5bn | USD 554.4bn | +15.1% |
| EBIT | USD 11.3bn | USD 13.0bn | USD 14.9bn | USD 17.2bn | USD 19.8bn | +15.1% |
| NOPAT | USD 9.1bn | USD 10.5bn | USD 12.1bn | USD 13.9bn | USD 16.0bn | +15.1% |
| Add depreciation & amortisation | USD 4.2bn | USD 4.8bn | USD 5.6bn | USD 6.4bn | USD 7.4bn | +15.1% |
| Less capital expenditure | USD -3.2bn | USD -3.6bn | USD -4.2bn | USD -4.8bn | USD -5.5bn | +15.1% |
| Less increase in working capital | USD 333.2m | USD 383.7m | USD 441.8m | USD 508.7m | USD 585.8m | -15.1% |
| Free cashflow to firm | USD 10.5bn | USD 12.1bn | USD 13.9bn | USD 16.0bn | USD 18.4bn | +15.1% |
| Discount factor | 0.9677 | 0.9062 | 0.8485 | 0.7946 | 0.7441 | - |
| Present value | USD 10.1bn | USD 10.9bn | USD 11.8bn | USD 12.7bn | USD 13.7bn | +7.8% |
| Present Value Of The Forecast | USD 59.3bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.542 | Reported 0.317, pulled toward 1.0 (Blume) |
| Cost of equity | 7.98% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 72.7bn | 69.8% of capital |
| Total debt | USD 31.5bn | 30.2% of capital, book value as a proxy |
| Tax rate | 19.2% | Effective, capped at statutory |
| WACC | 6.79% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
82% of EV
- Forecast FCFF, final year
- USD 18.4bn
- Capex at depreciation, working capital in reinvestment
- USD 21.4bn
- Less reinvestment at g/ROIC (29.8% of NOPAT)
- USD -6.4bn
- Capitalised
- USD 15.0bn
- ROIC (reported)
- 8.4%
- Terminal value, undiscounted
- USD 359.5bn
- Terminal value, discounted
- USD 267.5bn
- Enterprise value
- USD 326.8bn
- Less net debt
- USD 22.8bn
- Equity value
- USD 304.0bn
Exit at 8.7x EBITDA
75% of EV
- Terminal value, undiscounted
- USD 237.7bn
- Terminal value, discounted
- USD 176.9bn
- Enterprise value
- USD 236.2bn
- Less net debt
- USD 22.8bn
- Equity value
- USD 213.3bn
Spread between methods: 35%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 4.79% | 1785.12 | 1947.27 | 2178.53 | 2536.79 | 3169.69 |
| 5.79% | 1344.99 | 1411.12 | 1496.23 | 1610.50 | 1773.06 |
| 6.79% | 1071.44 | 1098.84 | 1131.79 | 1172.51 | 1224.52 |
| 7.79% | 885.02 | 894.44 | 904.99 | 917.04 | 931.11 |
| 8.79% | 756.05 | 759.16 | 762.27 | 765.37 | 768.48 |
Outlined: this model. Green text: above today's price of 275.28. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 15.1% | -11.7% | -26.8pp |
| EBIT margin | 3.6% | 0.3% | -3.3pp |
| Discount rate | 6.8% | 19.2% | +12.4pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.